April 19, 2017
Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
Media
April 19, 2017
GenSight Biologics to Attend Upcoming Investor Conferences
April 18, 2017
Cerenis Therapeutics announces the initiation of the Phase 1 clinical study with CER-209 in NAFLD and NASH
April 11, 2017
BONESUPPORT™ appoints Michael Diefenbeck as Chief Medical Officer
April 06, 2017
Report from Orexo AB´s annual general meeting, April 6 2017
April 06, 2017
Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
April 05, 2017
Final Phase 2 results for WTX101 accepted as a late-breaker presentation at EASL Annual Meeting
March 31, 2017
Exercise of the over-allotment option
March 28, 2017
Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
March 28, 2017
GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS
